KRAS and colorectal carcinoma: Collectively, our findings suggest that combined evaluation of MSI status, KRAS and BRAF mutation, and immune cell infiltration (cytotoxic T cells) may provide added value compared to each variable alone and might have potential to help guide decisions on immunotherapy in CRC.